A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

NCT06094296 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

NSCLC

Interventions

DRUG: BMS-986315
DRUG: Nivolumab
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Bristol-Myers Squibb